Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 12:54:41 16/07/2024 pm IST 5-day change 1st Jan Change
257.2 CHF -0.60% Intraday chart for Roche Holding AG +5.15% +5.19%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
ROCHE HOLDINGS AG : Sell rating from Goldman Sachs ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating ZD
DexCom, Inc. : A Must-Have Tool for Diabetes Care Our Logo
Markets Powered by Alternating Current Our Logo
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating ZD
ROCHE HOLDINGS AG : UBS gives a Neutral rating ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS MT
Swiss Market Index Closes in the Red; Roche Rises MT
Mixed feelings Our Logo
ROCHE HOLDINGS AG : UBS remains Neutral ZD
Roche: CE marking in diabetes monitoring CF
Roche Secures CE Mark for AI-powered Continuous Glucose Monitoring Device MT
Roche Receives CE Mark for Its AI-Enabled Continuous Glucose Monitoring Solution Offering Critical Predictions to People Living with Diabetes CI
Roche Secures FDA Nod to Relaunch Susvimo in US After Recall MT
Roche launches recalled eye implant in US RE
Roche Gets FDA Approval to Reintroduce Eye Implant Susvimo to the U.S. DJ
Roche: reintroduces Susvimo, FDA validates updates CF
Roche reintroduces recalled eye implant in US RE
Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration CI
Global markets live: Apple, Samsung, Shell, Tesla, KKR... Our Logo
Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals DJ
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating ZD
Roche: new approval for Vabysmo in the United States CF
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating ZD
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.7 CHF
Average target price
274 CHF
Spread / Average Target
+5.91%
Consensus
1st Jan change Capi.
+5.19% 23TCr
+63.05% 86TCr
+38.73% 63TCr
-4.78% 36TCr
+17.52% 32TCr
+8.43% 30TCr
+13.40% 24TCr
+16.32% 23TCr
+14.63% 18TCr
+1.08% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Secures CE Mark for AI-powered Continuous Glucose Monitoring Device